Although a number of studies have reported on PI3K pathway activation in HER2-positive breast cancer, they have been focused mainly on its impact on response to anti-HER2 therapy in metastatic disease or in the adjuvant setting [18, 28–30]. The gene discussed is PIK3CA; the disease is breast carcinoma.